[1]李立芳,韩宝林.早期乳腺癌根治术后辅助放疗指征探讨[J].国际放射医学核医学杂志,2013,37(5):287-291.[doi:10.3760/cma.j.issn.1673-4114.2013.05.009]
　LI Li-fang,HAN Bao-lin.Indications for postmastectomy radiotherapy in early breast cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):287-291.[doi:10.3760/cma.j.issn.1673-4114.2013.05.009]
点击复制

早期乳腺癌根治术后辅助放疗指征探讨(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第5期
页码:
287-291
栏目:
论著
出版日期:
2013-09-25

文章信息/Info

Title:
Indications for postmastectomy radiotherapy in early breast cancer patients
作者:
李立芳;  韩宝林
301800 天津, 天津市宝坻区人民医院放疗科
Author(s):
LI Li-fang;  HAN Bao-lin
Department of Radiation Oncology, Tianjin Baodi Hospital, Tianjin 301800, China
关键词:
乳腺肿瘤; 淋巴结; 肿瘤复发; 局部; 乳房切除术; 根治性; 放射疗法
Keywords:
Breast neoplasms; Lymph nodes; Neoplasm recurrence;  local; Mastectomy;  radical; Radiotherapy
DOI:
10.3760/cma.j.issn.1673-4114.2013.05.009
摘要:
目的 探讨腋窝淋巴结阳性数为1~3个的早期乳腺癌患者根治术后辅助放疗的指征。方法 回顾性分析根治术后并经病理证实腋窝淋巴结阳性数为1~3个的早期乳腺癌患者92例,腋窝淋巴结阳性数为1、2、3个的患者数分别为40、30、22例.其中45例接受同侧胸壁、内乳区及锁骨上淋巴引流区放疗。定义预后指数≥4分者为高危患者,<4分者为低危患者.采用Kaplan-Meier法计算生存率,并用Logrank法进行检验。结果 放疗患者和未放疗患者的5年生存率分别为93.5%和86.4%(χ2=3.43,P>0.05),10年生存率分别为73.0%和56.8%(χ2=2.82,P>0.05),局部复发率为6.7%和19.1%(χ2=4.66,P<0.05)。低危和高危患者中未放疗患者的10年生存率分别为73.0%和56.8%(χ2=3.45,P>0.05),局部复发率分别为11.0%和24.0% (χ2=4.64,P<0.05)。低危和高危患者中接受放疗患者的10年生存率分别为82.0%和72.3%(χ2=4.07,P<0.05),局部复发率分别为11.0%和5.0%(χ2=5.64,P<0.05)。结论 对腋窝淋巴结阳性数为1~3个的早期乳腺癌根治术后且预后指数为高危的患者,建议术后行胸壁和同侧锁骨上淋巴结辅助放疗。
Abstract:
Objective To explore the indications for postmastectomy radiotherapy in early breast cancer patients with 1-3 positive axillary lymph nodes.Methods Ninety-two early breast cancer patients with 1-3 pathologically confirmed positive axillary lymph nodes after radical mastectomy were retrospectively analyzed.Of these patients, 45 received irradiation to the lateral chest wall, internal mammary chain and supraclavicular area.The prognostic index ≥4 was considered as high-risk, while <4 as the low-risk.Survival analysis was performed using the Kaplan-Meier method.The Logrank test was used for the comparison of survival curves between different groups.Results The 5-year survival rates of patients with and without radiotherapy were 93.5% and 86.4% (χ2=3.43, P>0.05), the 10-year survival rates were 73.0% and 56.8%(χ2=2.82, P>0.05), the 10-year local recurrence rates wcrc 6.7% and 19.1% (χ2=4.66, P<0.05).The 10-year survival rates of patients with low risk and high risk without radiotherapy were 73.0% and 56.8% (χ2=3.45, P>0.05), while the local recurrence rates were 11.0% and 24.0% (χ2=4.64, P<0.05).The 10-year survival rates of patients with low risk and high risk with radiotherapy were 82.0% and 72.3% (χ2=4.07, P<0.05), while the local recurrence rates were 11.0% and 5.0% (χ2=5.64, P<0.05).Conclusion The early breast cancer patients with 1-3 positive axillary lymph nodes after radical mastectomy and the prognostic index suggests "high-risk" should receive irradiation to the chest wall and supraclavicular area.

参考文献/References:

[1] Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy:clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol, 2001, 19(5):1539-1569.
[2] Olivotto IA, Truong PT, Chua B. Postmastectomy radiation therapy:who needs it?. J Clin Oncol, 2004, 22(21):4237-4239.
[3] Russell NS, Kunkler IH, van Tienhoven G, et al. Postmastectomy radiotherapy:will the selective use of postmastectomy radiothera-py study end the debate?. J Clin Oncol, 2009, 27(6):996-997.
[4] Van Belle V, Van Calster B, Brouckaert O, et al. Qualitative assess-ment of the progesterone receptor and HER2 improves the Notting-ham Prognostic Index up to 5 years after breast cancer diagnosis. J Clin Oncol, 2010, 28(27):4129-4134.
[5] Puente J, López-Tamjella S, Ruiz A, et al. Practical prognostic index for patients with metastatic recurrent breast cancer:retro-spective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. Breast Cancer Res Treat, 2010, 122(2):591-600.
[6] van Nes JG, Putter H, van Hezewijk M, et al. Tailored follow-up for early breast cancer patients:a prognostic index that predicts locoregional recurrence. Eur J Surg Oncol, 2010,36(7):617-624.
[7] 蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学.4版.北京:中国协和医科大学出版社,2008:1179.
[8] Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamox-ifen without irradiation:experience of the Eastern Cooperative Oncology Group. J Clin Oncol, 1999, 17(6):1689-1700.
[9] 王慧颖,董慧婷,刘群,等.腋淋巴结切除数目在判断腋淋巴结阴性乳腺癌患者预后中的作用.中华肿瘤杂志,2012,34(6):457-460.
[10] Iyer RV, Hanlon A, Fowble B, et al. Accuracy of the extent of axil-lary nodal positivity related to primary tumor size, number of involved nodes, and number of nodes examined. Int J Radiat Oncol Biol Phys, 2000, 47(5):1177-1183.
[11] Van der Hage JA, Putter H, Bonnema J,et al. Impact of locoregion-al treatment on the early-stage breast cancer patients:a retrospec-tive analysis. Eur J Cancer, 2003, 39(15):2192-2199.
[12] 王淑莲,余子豪,李晔雄,等.T1~T2期伴1~3个腋窝淋巴结转移乳腺癌患者改良根治术后放疗的作用.中华放射肿瘤学杂志,2009:18(4):291-294.
[13] Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmas-tectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A sub-group analysis of the DBCG 82 b&c randomized trials. RadiotherOncol, 2007,82(3):247-253.
[14] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology-breast cancer guidelines 2011[EB/OL].[2013-01-03]. http://www.nccn.org.
[15] Rangan AM, Ahern V,Yip D, et al. Local recurrence after mastec-tomy and adjuvant CMF:implications for adjuvant radiation ther-apy. Aust N Z J Surg, 2000, 70(9):649-655.
[16] Cheng JC, Chen CM, Liu MC, et al. Locoregional failure of post-mastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy. Int J Radiat Oncol Biol Phys, 2002, 52(4):980-988.
[17] Fodor J, Polgdr C, Major T, et al. Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation. Strahlenther Onkol, 2003, 179(3):197-202.
[18] 王淑莲,李雄,余子豪, 等.早期乳腺癌根治术后放射治疗靶区的确定.中华放射肿瘤学杂志,2001,10(4):223-227.
[19] Obedian E, Haffty BG. Internal mammary nodal irradiation in con-servatively-managed breast cancer patients:is there a benefit?. Int J Radiat Oncol Biol Phys, 1999, 44(5):997-1003.
[20] 薛鸣,郑荣辉,廖志伟,等.乳腺癌术后内乳区放疗的临床意义.现代医院,2007,7(3):66-68.
[21] 陈忠杰,庄洪卿,郝建磊,等.早期乳腺癌患者预后因素分析.中国肿瘤临床,2011,38(9):524-528.
[22] Wilson CB, Haba Y, Wishart GC. The identification of patients for postmastectomy radiotherapy using the Cambridge index:audit of a prospective series. Breast Cancer Res Treat, 2007, 106(Suppll):S198.

相似文献/References:

[1]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
　Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[2]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
　Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[3]储小飞,赵舒怡,樊赛军.肿瘤干细胞与辐射抗性的研究进展[J].国际放射医学核医学杂志,2015,39(5):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
　chu xiaofei,zhao shuyi,fan saijun..advance progress of cancer stem cells and radioresistance[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
[4]陈伟君,孙达.99Tcm-MIBI显像在乳腺癌新辅助化疗中的应用价值[J].国际放射医学核医学杂志,2015,39(6):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
　Chen Weijun,Sun Da.Clinical value of 99Tcm-MIBI imaging in neoadjuvant chemotherapy of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
[5]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
　Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[6]黄娟,颜剑豪,梁联保,等.注射钆剂后弥散加权成像对乳腺肿瘤诊断的影响[J].国际放射医学核医学杂志,2015,39(4):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
　Huang Juan,Yan Jianhao,Liang Lianbao,et al.Evaluation of the diffusion-weighted imaging after contrast for the characterization of breast tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
[7]李雯,冯彦林.18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展[J].国际放射医学核医学杂志,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
　Li Wen,Feng Yanlin.Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
[8]殷丽娜,张旭霞,张俊香,等.Wnt/β-catenin信号通路——乳腺癌的潜在治疗靶点[J].国际放射医学核医学杂志,2014,38(4):252.[doi:10.3760/cma.j.issn.1673-4114.2014.04.011]
　Yin Lina,Zhang Xuxia,Zhang Junxiang,et al.The Wnt/β-catenin signaling pathway-a potential therapeutic target of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):252.[doi:10.3760/cma.j.issn.1673-4114.2014.04.011]
[9]刘超,邓智勇,刘鹏杰,等.89SrCL2与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析[J].国际放射医学核医学杂志,2014,38(5):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
　Liu Chao,Deng Zhi-yong,Liu Peng-jie,et al.Analysis on the curative effect of combination therapy with zoledronic acid and 89SrCL2 on bone tumor with breast cancer metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
[10]胡梦裳,章斌.PET/CT显像在乳腺癌疗效评价及预后中的作用[J].国际放射医学核医学杂志,2014,38(5):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
　Hu Meng-shang,Zhang Bin.The role of PET/CT imaging in the evaluation of the efficacy and prognosis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]

备注/Memo

备注/Memo:
收稿日期:2013-01-03。
通讯作者:李立芳,Email:dafang_007@126.com
更新日期/Last Update: 1900-01-01